Dr. Reddy’s names Teva vet COO
Erez Israeli succeeds 15-year COO Mukherjee
Dr. Reddy’s Labs recently made changes to its senior leadership team, spurred by the retirement of COO Abhijit Mukherjee on March 31 after 15 years with the company. Erez Israeli succeeded Mukherjee, effective April 2, becoming the company’s COO and global head of generics and pharmaceutical services and active ingredients.
In his new role, he will report to Dr. Reddy’s co-chairman and CEO G.V. Prasad. Israeli has previously served as president and CEO of Enzymotec, and has more than 25 years’ experience in the pharmaceutical industry. Twenty-three of those years were spent with Teva, where he held various leadership positions, including vice president of North American marketing and sales, vice president of Asia operations, group executive vice president, head of global quality and president and CEO of growth markets, among others.
“I would like to thank Abhijit for his valuable contribution to our company’s growth journey over the past fifteen years,” Prasad said. “I extend a warm welcome to Erez Israeli. Erez is an accomplished leader with a proven track record of achievement. His knowledge and experience from leading pharmaceutical businesses of scale will be valuable for our future growth.”
West-Ward brings generic Aloxi to market
West-Ward Pharmaceuticals, the U.S. subsidiary of Hikma Pharmaceuticals, has launched its generic Aloxi (palonosetron hydrochloriden injection). The drug is indicated to prevent acute nausea and vomiting associated with chemotherapy in adults. West-Ward’s generic Aloxi is the third generic of the product to launch in recent weeks.
“We are very pleased to add Palonosetron HCI Injection to our oncology portfolio,” West-Ward injectables division CEO Riad Mechlauoui said. “The launch of this product further expands our broad Injectables portfolio, bringing value to our customers and patients in the US hospital setting, as well as driving long-term, sustainable growth for our business.”
The drug, which the company is introducing in 0.25 mg/2 ml dosage strength, had a U.S. market size of $447 million for the 12 months ended January 2018.
FDA approves Amerigen’s generic cyclophosphamide
The Food and Drug Administration has approved Amerigen Pharmaceuticals’ abbreviated new drug application for two dosage strengths of its cyclophosphamide capsules. The drug, a generic of West-Ward’s product, is an anti-neoplastic agent indicated to treat various cancers.
Amerigen’s generic cyclophosphamide will be available in 25- and 50-mg capsules. The company said it plans to launch the drug soon, manufactured by Irvine Pharmaceuticals.